Show simple item record

dc.contributor.authorThornton, CR
dc.date.accessioned2019-11-04T09:13:12Z
dc.date.issued2019-11-20
dc.description.abstractFungi are an important but frequently overlooked cause of morbidity and mortality in humans. Life-threatening fungal infections mainly occur in immunocompromised patients, and are typically caused by environmental opportunists that take advantage of a weakened immune system. The filamentous fungus Aspergillus fumigatus is the most important and well-documented mould pathogen of humans, causing a number of complex respiratory diseases, including invasive pulmonary aspergillosis, an often fatal disease in patients with acute leukemia or in immunosuppressed bone marrow or solid organ transplant recipients. However, non-Aspergillus moulds are increasingly reported as agents of disseminated diseases, with Fusarium, Scedosporium, Lomentospora and mucormycete species now firmly established as pathogens of immunosuppressed and immunocompetent individuals. Despite well-documented risk factors for invasive fungal diseases, and increased awareness of the risk factors for life-threatening infections, the number of deaths attributable to moulds is likely to be severely underestimated driven, to a large extent, by the lack of readily accessible, cheap, and accurate tests that allow detection and differentiation of infecting species. Early diagnosis is critical to patient survival but, unlike Aspergillus diseases, where a number of CE-marked or FDA-approved biomarker tests are now available for clinical diagnosis, similar tests for fusariosis, scedosporiosis and mucormycosis remain experimental, with detection reliant on insensitive and slow culture of pathogens from invasive bronchoalveolar lavage fluid, tissue biopsy, or from blood. This review examines the ecology, epidemiology, and contemporary methods of detection of these mould pathogens, and the obstacles to diagnostic test development and translation of novel biomarkers to the clinical setting.en_GB
dc.description.sponsorshipInnovate UKen_GB
dc.identifier.citationPublished online 20 November 2019en_GB
dc.identifier.doi10.1016/bs.aambs.2019.10.003
dc.identifier.grantnumber105440en_GB
dc.identifier.urihttp://hdl.handle.net/10871/39483
dc.language.isoenen_GB
dc.publisherElsevieren_GB
dc.rights.embargoreasonUnder embargo until 20 November 2020 in compliance with publisher policyen_GB
dc.rights© 2019. This version is made available under the CC-BY-NC-ND 4.0 license https://creativecommons.org/licenses/by-nc-nd/4.0/ en_GB
dc.subjectAspergillusen_GB
dc.subjectaspergillosisen_GB
dc.subjectFusariumen_GB
dc.subjectLomentosporaen_GB
dc.subjectScedosporiumen_GB
dc.subjectmucormycosisen_GB
dc.subjectmonoclonal antibodyen_GB
dc.subjectlateral-flow deviceen_GB
dc.subjectfungal diagnosticsen_GB
dc.subjectmycosesen_GB
dc.titleDetection of the ‘Big Five’ mold killers of humans: Aspergillus, Fusarium, Lomentospora, Scedosporium and Mucormycetesen_GB
dc.typeArticleen_GB
dc.date.available2019-11-04T09:13:12Z
dc.identifier.issn0065-2164
dc.descriptionThis is the author accepted manuscript. The final version is available from Elsevier via the DOI in this recorden_GB
dc.identifier.journalAdvances in Applied Microbiologyen_GB
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/ en_GB
dcterms.dateAccepted2019-10-21
rioxxterms.versionAMen_GB
rioxxterms.licenseref.startdate2019-10-21
rioxxterms.typeJournal Article/Reviewen_GB
refterms.dateFCD2019-11-04T09:04:06Z
refterms.versionFCDAM
refterms.dateFOA2020-11-20T00:00:00Z
refterms.panelAen_GB


Files in this item

This item appears in the following Collection(s)

Show simple item record

© 2019. This version is made available under the CC-BY-NC-ND 4.0 license https://creativecommons.org/licenses/by-nc-nd/4.0/ 
Except where otherwise noted, this item's licence is described as © 2019. This version is made available under the CC-BY-NC-ND 4.0 license https://creativecommons.org/licenses/by-nc-nd/4.0/